Chimeric AAT-Fc Polypeptides for Autoimmune Diabetes Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, particularly Type 1 and Type 2, are not optimal, with existing therapies either ineffective after the onset of hyperglycemia or associated with risks such as hypersensitivity reactions and short metabolic half-life of administered proteins like AAT, necessitating frequent dosing and potential transmission of infectious agents.
Innovation Solution
Development of purified, recombinant chimeric AAT-Fc polypeptides conjugated to an Fc region of an immunoglobulin, which have a longer circulating half-life and enhanced activity in inhibiting serine proteases, offering a more effective treatment for autoimmune diabetes by increasing the stability and safety of AAT administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If AAT is administered to treat autoimmune diabetes, then therapeutic benefit is achieved, but the metabolic half-life is short requiring frequent dosing
Solution Approach 1:
The patent combines AAT with the Fc region of immunoglobulin to create a chimeric molecule. This merging allows the AAT to utilize the Fc region's interaction with the neonatal Fc receptor (FcRn) recycling pathway, thereby extending its metabolic half-life from approximately 5-6 days to potentially months, significantly reducing dosing frequency while maintaining therapeutic efficacy.
2Reliability
If AAT is administered to treat autoimmune diabetes, then therapeutic benefit is achieved, but hypersensitivity reactions occur
Solution Approach 1:
The patent uses recombinant DNA technology to create a synthetic copy of AAT with modified properties. By copying the AAT gene sequence and expressing it in a controlled recombinant system, the resulting protein has identical or improved therapeutic function but eliminates risks associated with plasma-derived AAT, including hypersensitivity reactions and transmission of infectious agents.
3Reliability
If plasma-derived AAT is used, then treatment is available, but transmission of infectious agents is a risk
Solution Approach 1:
The patent replaces plasma-derived AAT with recombinant AAT produced in cell culture systems. By copying the AAT gene and expressing it in controlled environments, the invention eliminates the risk of transmitting viral or prionic infections from human plasma while maintaining full therapeutic activity and availability.
4Reliability
If commercial AAT preparations are used, then treatment is provided, but activity is limited compared to purified recombinant forms
Solution Approach 1:
The patent uses recombinant DNA technology to create pure copies of the AAT protein in cell culture systems. This approach produces highly purified AAT with consistent, high-specific activity that exceeds commercial preparations, while the modular expression system simplifies purification through affinity tags and controlled secretion pathways.
Data Source
AI summary
The specification provides compositions comprising chimeric proteins comprising AAT conjugated to an Fc region of an immunoglobulin. Methods for treating autoimmune disease, e.g., diabetes, e.g., Type 1 and Type 2 diabetes, are also provided.